StockNews.com downgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) from a strong-buy rating to a buy ...

Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) had its price target raised by HC Wainwright from $30.00 to $35.00 ...

Catalyst Pharmaceuticals Inc. closed $2.35 short of its 52-week high ($24.27), which the company reached on November 8th.

Oppenheimer raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $31 from $29 and keeps an Outperform rating on the shares.

Catalyst Pharmaceuticals, Inc. has announced a settlement agreement with Teva Pharmaceuticals, resolving the patent ...

It was a busy week in the biotech sector, with many regulatory and pipeline updates. Neumora Therapeutics NMRA plummeted on the announcement of a study failure, while Hoth Therape ...

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...

Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Stephens has recently initiated Catalyst Pharmaceuticals Inc (CPRX) stock to Overweight rating, as announced on November 18, 2024, according to Finviz. Earlier, on March 14, 2024, Citigroup had ...

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing ...

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Catalyst Pharma (CPRX – Research Report), ...